News

Practice Changers Expected at San Antonio Breast Cancer Symposium


 

The 2011 San Antonio Breast Cancer Symposium that opened Dec. 6 features a hefty number of studies that could change clinical practice in the treatment of breast cancer.

Oncologists have been eagerly awaiting data from the phase III BOLERO-2 and CLEOPATRA trials, which are to be presented Dec. 8 and 9, respectively.

– BOLERO-2 investigators reported that pairing everolimus (Afinitor) with exemestane (Aromasin) increased median progression-free survival by 4.1 months in an interim analysis presented this fall at the European Multidisciplinary Cancer Congress in Stockholm. Women in this study had estrogen receptor-positive disease that was resistant to hormone therapy.

– Genentech announced last summer that dual HER2 blockade with pertuzumab* and trastuzumab (Herceptin) improved progression-free survival for women with HER2-positive disease who also received docetaxel (Taxotere) in CLEOPATRA. The pairing has also produced good results in the NeoSphere trial, and early reports from studies pairing lapatinib (Tykerb) with trastuzumab have been encouraging.

On Dec. 7, an early-morning press briefing has been scheduled for investigators to outline findings of four noteworthy studies.

– Swedish researchers will report that diabetes and obesity after age 60 are risk factors for breast cancer. Low lipids also increased risk, but high lipids did not in their study comparing medical records of more than 23,000 women. Similarly, risk went up with use of the diabetes drug glargine but down with metformin.

– Gene expression patterns at diagnosis of hormone receptor–positive breast cancer can predict which women will have recurrences late, early, or not at all, according to researchers from the United States.

– Women treated with brachytherapy were about twice as likely to undergo subsequent mastectomy when compared with those treated by whole breast irradiation in a study of more than 150,000 Medicare claims.

– A ductal carcinoma in situ (DCIS) risk score based on the multigene Oncotype DX assay has been validated for prediction of breast cancer recurrence in DCIS patients.

Other Dec. 7 highlights will include presentations from four studies of bisphosphonate use in breast cancer patients and an Institute of Medicine report on "Breast Cancer and the Environment."

For ongoing coverage of these and other presentations at the San Antonio Breast Cancer Symposium, visit http://www.oncologyreport.com.

*Correction, Dec. 8, 2011: An earlier version of this story referred to pertuzumab by the trade name Omnitarg. That trade name was discontinued by Genentech in 2007 and currently the drug goes by pertuzumab.

Recommended Reading

Cancer Often Goes Untreated in Nursing Home Residents
MDedge Hematology and Oncology
Prostate: Denosumab Extends Bone Metastasis-Free Survival
MDedge Hematology and Oncology
Half of Older Cancer Patients Have Unrecognized Medical Problems
MDedge Hematology and Oncology
Mortality Greatest With Recurrence of Papillary Type Thyroid Cancer
MDedge Hematology and Oncology
Walking Ability Aids Assessment of Elderly Breast Cancer Patients
MDedge Hematology and Oncology
JAK Inhibitor Ruxolitinib Wins First FDA Approval in Myelofibrosis
MDedge Hematology and Oncology
FDA Revokes Avastin Approval for Breast Cancer
MDedge Hematology and Oncology
Discussing End-of-Life Planning with Patients
MDedge Hematology and Oncology
Study Supports HBV Screening, Prophylaxis in Chemotherapy Patients
MDedge Hematology and Oncology
Coronary Disease, Stroke to Drop Below Cancer as Top Killer
MDedge Hematology and Oncology

Related Articles